Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-30 09:50:02 Page View：98

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： NYU radiologists take on the challenge of expensive MRI machines
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

FDA's Woodcock to retire early next year

PrincipalDeputyFDACommissionerJanetWoodcockStefaniReynolds/TheNewYorkTimesviaAPWASHINGTON—PrincipalD

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Timeline: How the deadly wildfires took over Maui day by day

5:04InthisimageobtainedfromtheCountyofMauiinHawaii,showsawildfireinLahaina,onAug.9,2023.Hawaiiwildfi